File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials

TitleEffect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials
Authors
KeywordsAutosomal dominant polycystic kidney disease
End-stage renal disease
Glomerular filtration rate
HALT PKD trials
Hydroxymethylglutaryl-CoA reductase inhibitors
Total kidney volume
Issue Date2017
Citation
Current Hypertension Reviews, 2017, v. 13, n. 2, p. 109-120 How to Cite?
AbstractBackground: Autosomal dominant polycystic kidney disease (ADPKD) commonly results in end-stage renal disease (ESRD), yet a long-term treatment that is well tolerated is still lacking. In a small randomized trial in children and adolescents pravastatin administration for 3 years was associated with reduced renal cyst growth, but no large trial has tested the effect of statins in adults. Methods: We performed a post-hoc analysis of the HALT PKD trials to compare outcomes of participants who never used statins with those who used statin for at least 3 years. Because statins were not randomly allocated, we used propensity score models with inverse probability of treatment weighting to account for imbalances between the groups. For subjects in Study A (preserved renal function, n=438) relevant outcomes were percent change in total kidney and liver volume and the rate of decline in estimated glomerular filtration rate (eGFR); for those in Study B (reduced renal function, n=352) we compared time to the composite endpoint of death, ESRD or 50% decline in eGFR. Follow-up was 5-8 years. Results: There was no difference in any outcome between the 2 groups. However, limitations of this analysis are the small number of statin users in Study A, different statin drugs and doses used, non-randomized allocation and advanced disease stage in Study B. Conclusion: Although this post-hoc analysis of the HALT PKD trials does not demonstrate a benefit of statin therapy, conclusions remain preliminary. A larger randomized trial in young people with ADPKD is necessary to answer the question whether statins can slow renal cyst growth and preserve kidney function.
Persistent Identifierhttp://hdl.handle.net/10722/316151
ISSN
2023 Impact Factor: 1.5
2023 SCImago Journal Rankings: 0.598
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBrosnahan, Godela M.-
dc.contributor.authorAbebe, Kaleab Z.-
dc.contributor.authorRahbari-Oskoui, Frederic F.-
dc.contributor.authorPatterson, Charity G.-
dc.contributor.authorBae, Kyongtae T.-
dc.contributor.authorSchrier, Robert W.-
dc.contributor.authorBraun, William E.-
dc.contributor.authorChapman, Arlene B.-
dc.contributor.authorFlessner, Michael F.-
dc.contributor.authorHarris, Peter C.-
dc.contributor.authorPerrone, Ronald D.-
dc.contributor.authorSteinman, Theodore I.-
dc.contributor.authorTorres, Vicente E.-
dc.date.accessioned2022-08-24T15:49:25Z-
dc.date.available2022-08-24T15:49:25Z-
dc.date.issued2017-
dc.identifier.citationCurrent Hypertension Reviews, 2017, v. 13, n. 2, p. 109-120-
dc.identifier.issn1573-4021-
dc.identifier.urihttp://hdl.handle.net/10722/316151-
dc.description.abstractBackground: Autosomal dominant polycystic kidney disease (ADPKD) commonly results in end-stage renal disease (ESRD), yet a long-term treatment that is well tolerated is still lacking. In a small randomized trial in children and adolescents pravastatin administration for 3 years was associated with reduced renal cyst growth, but no large trial has tested the effect of statins in adults. Methods: We performed a post-hoc analysis of the HALT PKD trials to compare outcomes of participants who never used statins with those who used statin for at least 3 years. Because statins were not randomly allocated, we used propensity score models with inverse probability of treatment weighting to account for imbalances between the groups. For subjects in Study A (preserved renal function, n=438) relevant outcomes were percent change in total kidney and liver volume and the rate of decline in estimated glomerular filtration rate (eGFR); for those in Study B (reduced renal function, n=352) we compared time to the composite endpoint of death, ESRD or 50% decline in eGFR. Follow-up was 5-8 years. Results: There was no difference in any outcome between the 2 groups. However, limitations of this analysis are the small number of statin users in Study A, different statin drugs and doses used, non-randomized allocation and advanced disease stage in Study B. Conclusion: Although this post-hoc analysis of the HALT PKD trials does not demonstrate a benefit of statin therapy, conclusions remain preliminary. A larger randomized trial in young people with ADPKD is necessary to answer the question whether statins can slow renal cyst growth and preserve kidney function.-
dc.languageeng-
dc.relation.ispartofCurrent Hypertension Reviews-
dc.subjectAutosomal dominant polycystic kidney disease-
dc.subjectEnd-stage renal disease-
dc.subjectGlomerular filtration rate-
dc.subjectHALT PKD trials-
dc.subjectHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subjectTotal kidney volume-
dc.titleEffect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2174/1573402113666170427142815-
dc.identifier.pmid28460625-
dc.identifier.scopuseid_2-s2.0-85034014959-
dc.identifier.volume13-
dc.identifier.issue2-
dc.identifier.spage109-
dc.identifier.epage120-
dc.identifier.eissn1875-6506-
dc.identifier.isiWOS:000447563000005-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats